Johnson & Johnson EBITDA 2010-2024 | JNJ
Johnson & Johnson annual and quarterly EBITDA history from 2010 to 2024. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
- Johnson & Johnson EBITDA for the quarter ending March 31, 2024 was $5.965B, a 27.24% increase year-over-year.
- Johnson & Johnson EBITDA for the twelve months ending March 31, 2024 was $24.581B, a 9.28% decline year-over-year.
- Johnson & Johnson 2023 annual EBITDA was $24.581B, a 9.28% decline from 2022.
- Johnson & Johnson 2022 annual EBITDA was $27.095B, a 1.09% increase from 2021.
- Johnson & Johnson 2021 annual EBITDA was $26.804B, a 11.5% increase from 2020.
Johnson & Johnson Annual EBITDA
(Millions of US $) |
| 2023 |
$24,581 |
| 2022 |
$27,095 |
| 2021 |
$26,804 |
| 2020 |
$24,040 |
| 2019 |
$25,012 |
| 2018 |
$26,544 |
| 2017 |
$24,634 |
| 2016 |
$24,651 |
| 2015 |
$23,622 |
| 2014 |
$25,058 |
| 2013 |
$20,131 |
| 2012 |
$18,037 |
| 2011 |
$16,181 |
| 2010 |
$20,448 |
| 2009 |
$19,070 |
Johnson & Johnson Quarterly EBITDA
(Millions of US $) |
| 2023-12-31 |
$5,965 |
| 2023-09-30 |
$7,612 |
| 2023-06-30 |
$9,411 |
| 2023-03-31 |
$1,593 |
| 2022-12-31 |
$4,688 |
| 2022-09-30 |
$7,058 |
| 2022-06-30 |
$7,686 |
| 2022-03-31 |
$7,663 |
| 2021-12-31 |
$3,154 |
| 2021-09-30 |
$5,696 |
| 2021-06-30 |
$8,553 |
| 2021-03-31 |
$9,401 |
| 2020-12-31 |
$3,687 |
| 2020-09-30 |
$6,275 |
| 2020-06-30 |
$5,730 |
| 2020-03-31 |
$8,348 |
| 2019-12-31 |
$6,200 |
| 2019-09-30 |
$3,511 |
| 2019-06-30 |
$8,917 |
| 2019-03-31 |
$6,384 |
| 2018-12-31 |
$5,303 |
| 2018-09-30 |
$6,572 |
| 2018-06-30 |
$7,069 |
| 2018-03-31 |
$7,600 |
| 2017-12-31 |
$4,788 |
| 2017-09-30 |
$6,804 |
| 2017-06-30 |
$6,230 |
| 2017-03-31 |
$6,812 |
| 2016-12-31 |
$5,663 |
| 2016-09-30 |
$6,478 |
| 2016-06-30 |
$6,082 |
| 2016-03-31 |
$6,428 |
| 2015-12-31 |
$5,004 |
| 2015-09-30 |
$5,206 |
| 2015-06-30 |
$6,785 |
| 2015-03-31 |
$6,627 |
| 2014-12-31 |
$3,850 |
| 2014-09-30 |
$7,897 |
| 2014-06-30 |
$6,720 |
| 2014-03-31 |
$6,591 |
| 2013-12-31 |
$4,004 |
| 2013-09-30 |
$4,766 |
| 2013-06-30 |
$5,918 |
| 2013-03-31 |
$5,443 |
| 2012-12-31 |
$4,261 |
| 2012-09-30 |
$4,750 |
| 2012-06-30 |
$3,044 |
| 2012-03-31 |
$5,982 |
| 2011-12-31 |
$1,379 |
| 2011-09-30 |
$5,045 |
| 2011-06-30 |
$4,346 |
| 2011-03-31 |
$5,411 |
| 2010-12-31 |
$3,159 |
| 2010-09-30 |
$5,065 |
| 2010-06-30 |
$5,075 |
| 2010-03-31 |
$7,149 |
| 2009-12-31 |
$3,453 |
| 2009-09-30 |
$5,090 |
| 2009-06-30 |
$5,077 |
| 2009-03-31 |
$5,450 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$360.407B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
